Terms of Reference

Overview

The type 2 novel oral poliovirus vaccine (nOPV2) is a modified version of the current Sabin OPV vaccine that provides comparable immunity against poliovirus whilst being more genetically stable. The vaccine has completed a phase I and two II trials in Belgium and Panama and found to be safe and immunogenic. Another Phase II trial has begun in newborn infants in Bangladesh and a Phase III trial will be launched in the Gambia in the coming months. The nOPV2 has been submitted for assessment under WHO’s Emergency Use Listing (EUL), a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics for use primarily during public health emergencies of international concern (PHEIC).